AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28525723 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest Pain Choice (CPC) decision aid
Number of subjects: 898
Study 28525723 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 898
Study 27678426 — intervention group
Group type: EXPERIMENTAL
Intervention: Low advanced glycation end products diet (L‐dAGEs)
Number of subjects: 62
Study 27678426 — intervention group
Group type: COMPARATOR
Intervention: Standard advanced glycation end products diet (S‐dAGEs)
Number of subjects: 62
Study 24886920 — intervention group
Group type: EXPERIMENTAL
Intervention: HFM+RE
Number of subjects: 9
Study 24886920 — intervention group
Group type: COMPARATOR
Intervention: HFM
Number of subjects: 9
Study 21889297 — intervention group
Group type: EXPERIMENTAL
Intervention: Teachers with self-reported voice problems
Number of subjects: 0
Study 21889297 — intervention group
Group type: COMPARATOR
Intervention: Teachers with self-reported voice health
Number of subjects: 0
Study 20136661 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine
Number of subjects: 600
Study 20136661 — intervention group
Group type: COMPARATOR
Intervention: Abacavir
Number of subjects: 600
Study 18354708 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency lesioning of the dorsal root ganglion/segmental nerve
Number of subjects: 76
Study 18354708 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed and continuous radiofrequency lesioning
Number of subjects: 76
Study 16193347 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate therapy
Number of subjects: 46
Study 16193347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 11709789 — intervention group
Group type: EXPERIMENTAL
Intervention: BBG2Na 10 microg
Number of subjects: 108
Study 11709789 — intervention group
Group type: EXPERIMENTAL
Intervention: BBG2Na 100 microg
Number of subjects: 108
Study 11709789 — intervention group
Group type: EXPERIMENTAL
Intervention: BBG2Na 300 microg
Number of subjects: 108
Study 11709789 — intervention group
Group type: EXPERIMENTAL
Intervention: BBG2Na (all doses)
Number of subjects: 108
Study 11709789 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 108
Study 9051434 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray 0.14 mg/nostril twice daily (0.56 mg/day)
Number of subjects: 125
Study 9051434 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 125
Study 8091174 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (2.0 ml 2%)
Number of subjects: 2
Study 8091174 — intervention group
Group type: COMPARATOR
Intervention: Articaine (2.0 ml 4%)
Number of subjects: 2
Study 3592320 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-hour cefazolin (4 intravenous injections of 1 g cefazolin over 12 hours)
Number of subjects: 159
Study 3592320 — intervention group
Group type: COMPARATOR
Intervention: 36-hour cefazolin (12 doses over 36 hours)
Number of subjects: 159
Study 29502160 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) for BMS
Number of subjects: 44
Study 29502160 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA) for BMS
Number of subjects: 44
Study 29502160 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) for SOB
Number of subjects: 44
Study 29502160 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA) for SOB
Number of subjects: 44
Study 29502160 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy female subjects)
Number of subjects: 44
Study 26552942 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone 20-60 mg/day
Number of subjects: 209
Study 26552942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study 23883379 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg semagacestat
Number of subjects: 1537
Study 23883379 — intervention group
Group type: EXPERIMENTAL
Intervention: 140 mg semagacestat
Number of subjects: 1537
Study 23883379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1537
Study 21538515 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 23
Study 21538515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 19655819 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with olmesartan medoxomil/HCTZ 20/25 mg/day
Number of subjects: 502
Study 19655819 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with olmesartan medoxomil/HCTZ 40/12.5 mg/day
Number of subjects: 502
Study 19655819 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with olmesartan medoxomil/HCTZ 40/25 mg/day
Number of subjects: 502
Study 19655819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 502
Study 19655819 — intervention group
Group type: EXPERIMENTAL
Intervention: HCTZ 12.5 or 25 mg/day
Number of subjects: 502
Study 19655819 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil 10, 20, or 40 mg/day
Number of subjects: 502
Study 16273313 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) + BCNU + standard radiation therapy (SRT)
Number of subjects: 451
Study 16273313 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) + BCNU + accelerated radiation therapy (ART)
Number of subjects: 451
Study 16273313 — intervention group
Group type: COMPARATOR
Intervention: Carmustine (BCNU) + standard radiation therapy (SRT)
Number of subjects: 451
Study 16273313 — intervention group
Group type: COMPARATOR
Intervention: Carmustine (BCNU) + accelerated radiation therapy (ART)
Number of subjects: 451
Study 15222409 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (20 mg)
Number of subjects: 100
Study 15222409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 11259892 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine 1% (1 mL/kg)
Number of subjects: 60
Study 11259892 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.25% (1 mL/kg)
Number of subjects: 60
Study 11259892 — intervention group
Group type: COMPARATOR
Intervention: Mixture of mepivacaine 1% and bupivacaine 0.25% (0.5 mL/kg each)
Number of subjects: 60
Study 9219213 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramp incremental rate trials
Number of subjects: 10
Study 9219213 — intervention group
Group type: COMPARATOR
Intervention: Constant power trials
Number of subjects: 10
Study 8356413 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifamycin SV
Number of subjects: 87
Study 8356413 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone acetonide
Number of subjects: 87
Study 8356413 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 87
Study 3278500 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal epidural (CSE) block
Number of subjects: 30
Study 3278500 — intervention group
Group type: COMPARATOR
Intervention: Epidural block
Number of subjects: 30
Study 3278500 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal epidural (CSE) block and Epidural block
Number of subjects: 30
Study 29682897 — intervention group
Group type: EXPERIMENTAL
Intervention: HR‐ADM plus standard of care (SOC)
Number of subjects: 80
Study 29682897 — intervention group
Group type: COMPARATOR
Intervention: SOC alone
Number of subjects: 80
Study 29682897 — intervention group
Group type: EXPERIMENTAL
Intervention: HR‐ADM plus SOC
Number of subjects: 80
Study 28054235 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated Humidified High-Flow Nasal Cannula (HHHFNC)
Number of subjects: 49
Study 28054235 — intervention group
Group type: COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 49
Study 26597979 — intervention group
Group type: EXPERIMENTAL
Intervention: Early goal-directed therapy (EGDT)
Number of subjects: 1260
Study 26597979 — intervention group
Group type: COMPARATOR
Intervention: Usual resuscitation
Number of subjects: 1260
Study 23611076 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma Affect Regulation: Guide for Education and Therapy (TARGET)
Number of subjects: 72
Study 23611076 — intervention group
Group type: COMPARATOR
Intervention: Supportive Group Therapy (SGT)
Number of subjects: 72
Study 21301135 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine hydrochloride plus conventional therapy
Number of subjects: 53
Study 21301135 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol plus conventional therapy
Number of subjects: 53
Study 21301135 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 53
Study 18466804 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Training (ET) for 2 months followed by 6 months of self-regulated training
Number of subjects: 24
Study 18466804 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Training (ET)
Number of subjects: 24
Study 18466804 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 23036114 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus ≥64-multidetector computed tomography coronary angiography and coronary calcium score
Number of subjects: 4138
Study 23036114 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 4138
Study 15711898 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonic Speed toothbrush in conjunction with the electric interdental cleaning device Flosser FL‐110 (Water Pik)
Number of subjects: 40
Study 15711898 — intervention group
Group type: COMPARATOR
Intervention: Manual interX short brush‐head toothbrush (elmex)
Number of subjects: 40
Study 15711898 — intervention group
Group type: COMPARATOR
Intervention: Sonic Speed SR‐100E sonic toothbrush (Water Pik)
Number of subjects: 40
Study 15711898 — intervention group
Group type: COMPARATOR
Intervention: Sonic Speed sonic toothbrush in conjunction with multi‐floss 3‐phase dental floss (elmex)
Number of subjects: 40
Study 12183280 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 2
Study 12183280 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole at 10.4 +/- 4.3 micro g/ml
Number of subjects: 2
Study 12183280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 11477859 — intervention group
Group type: EXPERIMENTAL
Intervention: RT plus Chinese herbal medicine
Number of subjects: 50
Study 11477859 — intervention group
Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 50
Study 7806958 — intervention group
Group type: EXPERIMENTAL
Intervention: Students with learning disabilities
Number of subjects: 0
Study 7806958 — intervention group
Group type: COMPARATOR
Intervention: Students without learning disabilities
Number of subjects: 0
Study 2514651 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicletanine 50 mg daily for 3 months
Number of subjects: 72
Study 2514651 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicletanine 100 mg daily for 3 months
Number of subjects: 72
Study 2514651 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during single-blind period)
Number of subjects: 72
Study 1097345 — intervention group
Group type: EXPERIMENTAL
Intervention: Total liver extract
Number of subjects: 40
Study 1097345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 29192837 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic Hamstring exercise (NHE)
Number of subjects: 35
Study 29192837 — intervention group
Group type: COMPARATOR
Intervention: Do-as-usual control group (CG)
Number of subjects: 35
Study 28285423 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezosurgery
Number of subjects: 49
Study 28285423 — intervention group
Group type: COMPARATOR
Intervention: Conventional osteotomy
Number of subjects: 49
Study 28285423 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 49
Study 26705233 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Hyaluronate Gel (SHG group)
Number of subjects: 114
Study 26705233 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitosan (CH group)
Number of subjects: 114
Study 26705233 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON group)
Number of subjects: 114
Study 23117218 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant Occupational Therapy (OT)
Number of subjects: 117
Study 23117218 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 117
Study 21048770 — intervention group
Group type: EXPERIMENTAL
Intervention: diet+PS (2 g/day of phytosterols)
Number of subjects: 75
Study 21048770 — intervention group
Group type: COMPARATOR
Intervention: diet (control group)
Number of subjects: 75
Study 18506005 — intervention group
Group type: EXPERIMENTAL
Intervention: RB006 (15 mg)
Number of subjects: 50
Study 18506005 — intervention group
Group type: EXPERIMENTAL
Intervention: RB006 (30 mg)
Number of subjects: 50
Study 18506005 — intervention group
Group type: EXPERIMENTAL
Intervention: RB006 (50 mg)
Number of subjects: 50
Study 18506005 — intervention group
Group type: EXPERIMENTAL
Intervention: RB006 (75 mg)
Number of subjects: 50
Study 18506005 — intervention group
Group type: EXPERIMENTAL
Intervention: RB007 (antidote)
Number of subjects: 50
Study 16517572 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing exercises focusing on shallow nasal breathing
Number of subjects: 57
Study 16517572 — intervention group
Group type: COMPARATOR
Intervention: Non‐specific upper body exercises
Number of subjects: 57
Study 12705316 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally and linguistically appropriate session on infant immunization
Number of subjects: 352
Study 12705316 — intervention group
Group type: COMPARATOR
Intervention: Session on prevention of Sudden Infant Death Syndrome
Number of subjects: 352
Study 10758792 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile oxytocin infusion
Number of subjects: 560
Study 10758792 — intervention group
Group type: COMPARATOR
Intervention: Continuous oxytocin infusion
Number of subjects: 560
Study 8970215 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin (20 mg/kg once daily)
Number of subjects: 111
Study 8970215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 1375873 — intervention group
Group type: EXPERIMENTAL
Intervention: OK-432 (intratumoral injection)
Number of subjects: 14
Study 1375873 — intervention group
Group type: COMPARATOR
Intervention: Control (non-injected)
Number of subjects: 14
Study 6385693 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin and Tobramycin with peak levels of 7 micrograms/ml or greater
Number of subjects: 37
Study 6385693 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin with peak levels of 28 micrograms/ml or greater
Number of subjects: 37
Study 6385693 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mean peak levels of 6 micrograms/ml or greater for Gentamicin and Tobramycin
Number of subjects: 37
Study 6385693 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mean peak levels of 24 micrograms/ml or greater for Amikacin
Number of subjects: 37
Study 29368187 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin with green tea extract (GTE) containing 150 mg of EGCG
Number of subjects: 11
Study 29368187 — intervention group
Group type: COMPARATOR
Intervention: Brewed green tea
Number of subjects: 11
Study 29368187 — intervention group
Group type: COMPARATOR
Intervention: Green tea extract (GTE)
Number of subjects: 11
Study 26858080 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month DAPT
Number of subjects: 1829
Study 26858080 — intervention group
Group type: COMPARATOR
Intervention: 12-month DAPT
Number of subjects: 1829
Study 25603389 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 2.5 mg
Number of subjects: 144
Study 25603389 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 5.0 mg
Number of subjects: 144
Study 25603389 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 7.5 mg
Number of subjects: 144
Study 25603389 — intervention group
Group type: COMPARATOR
Intervention: Control group (0.0 mg dexamethasone)
Number of subjects: 144
Study 23061407 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat and sibutramine treatment
Number of subjects: 101
Study 23061407 — intervention group
Group type: COMPARATOR
Intervention: Control group (without T allele)
Number of subjects: 101
Study 20090325 — intervention group
Group type: EXPERIMENTAL
Intervention: Erosion without dental plaque (EO)
Number of subjects: 4
Study 20090325 — intervention group
Group type: EXPERIMENTAL
Intervention: Erosion with plaque (EP)
Number of subjects: 4
Study 20090325 — intervention group
Group type: COMPARATOR
Intervention: Cariogenic challenge with plaque (CO)
Number of subjects: 4
Study 20090325 — intervention group
Group type: EXPERIMENTAL
Intervention: Erosion plus cariogenic challenge (EC)
Number of subjects: 4
Study 18188033 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (200 mg twice daily)
Number of subjects: 62
Study 18188033 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime (1 g three times a day)
Number of subjects: 62
Study 16763848 — intervention group
Group type: EXPERIMENTAL
Intervention: ADCON‐L Gel (ALG)
Number of subjects: 31
Study 16763848 — intervention group
Group type: COMPARATOR
Intervention: Preclude Spinal Membrane (PSM)
Number of subjects: 31
Study 15230300 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose glucocorticoids and immunosuppressive agents
Number of subjects: 0
Study 15230300 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical outcomes survey short form‐36 (SF-36)
Number of subjects: 0
Study 15230300 — intervention group
Group type: EXPERIMENTAL
Intervention: ACR/SLICC damage index
Number of subjects: 0
Study 15230300 — intervention group
Group type: EXPERIMENTAL
Intervention: Responder indices
Number of subjects: 0
Study 15230300 — intervention group
Group type: EXPERIMENTAL
Intervention: Area under the curve analysis
Number of subjects: 0
Study 12439362 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive saline hydration with the aim of keeping urine output over 150 mL/hour
Number of subjects: 0
Study 12439362 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-osmolality contrast agents with minimal volume
Number of subjects: 0
Study 12439362 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine DA1 agonist fenoldopam
Number of subjects: 0
Study 9133770 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 25
Study 9133770 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 7962669 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg S(‐)‐atenolol (SATN)
Number of subjects: 8
Study 7962669 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg racemic atenolol (RSATN)
Number of subjects: 8
Study 7962669 — intervention group
Group type: EXPERIMENTAL
Intervention: S(‐)‐atenolol (SATN)
Number of subjects: 8
Study 7962669 — intervention group
Group type: EXPERIMENTAL
Intervention: racemic atenolol (RSATN)
Number of subjects: 8
Study 3679915 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutron therapy
Number of subjects: 0
Study 3679915 — intervention group
Group type: COMPARATOR
Intervention: Photon therapy
Number of subjects: 0
Study 31575336 — intervention group
Group type: EXPERIMENTAL
Intervention: 384 preprocessing strategies applied to [11C]DASB-PET data
Number of subjects: 30
Study 31575336 — intervention group
Group type: EXPERIMENTAL
Intervention: Preprocessing strategies with motion correction
Number of subjects: 30
Study 31575336 — intervention group
Group type: EXPERIMENTAL
Intervention: Preprocessing strategies without motion correction
Number of subjects: 30
Study 30075691 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated species-level classification of echolocation clicks using supervised step-wise discriminant analysis and clustering routines.
Number of subjects: 0
Study 30075691 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectral clustering tested on clicks from encounters of beaked, sperm, and pilot whales.
Number of subjects: 0
Study 27103175 — intervention group
Group type: EXPERIMENTAL
Intervention: gedatolisib (PF-05212384)
Number of subjects: 58
Study 27103175 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-04691502
Number of subjects: 58
Study 26202325 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-supported upper limb training (3 weekly sessions of 30 min for 8 weeks)
Number of subjects: 17
Study 26202325 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment only
Number of subjects: 17
Study 23551622 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg once a day (OaD)
Number of subjects: 770
Study 23551622 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil on demand (PRN)
Number of subjects: 770
Study 23551622 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil on demand (PRN)
Number of subjects: 770
Study 23551622 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil OaD
Number of subjects: 770
Study 23551622 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil PRN
Number of subjects: 770
Study 23551622 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 770
Study 20074337 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based patient information (EBPI) about subthreshold elevated blood glucose levels and diabetes primary prevention
Number of subjects: 0
Study 20074337 — intervention group
Group type: COMPARATOR
Intervention: Information about elevated blood glucose levels and diabetes primary prevention available on the internet
Number of subjects: 0
Study 18194307 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with bypassing agents (FEIBA and NovoSeven)
Number of subjects: 48
Study 18194307 — intervention group
Group type: COMPARATOR
Intervention: Treatment with one bypassing agent (effective)
Number of subjects: 48
Study 17165494 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus antiasthma agents
Number of subjects: 104
Study 17165494 — intervention group
Group type: COMPARATOR
Intervention: Control group (antiasthma agents only)
Number of subjects: 104
Study 14592997 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole (1 mg)
Number of subjects: 20
Study 14592997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10516117 — intervention group
Group type: EXPERIMENTAL
Intervention: Early group (15 min after surgery)
Number of subjects: 16
Study 10516117 — intervention group
Group type: COMPARATOR
Intervention: Late group (49 min after surgery)
Number of subjects: 16
Study 10516117 — intervention group
Group type: EXPERIMENTAL
Intervention: Early group
Number of subjects: 16